Joel S Schuman1. 1. UPMC Eye Center, Eye and Ear Institute, Ophthalmology and Visual Science Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE: Optical coherence tomography (OCT) is a rapidly evolving, robust technology that has profoundly changed the practice of ophthalmology. Spectral domain OCT (SD-OCT) increases axial resolution 2- to 3-fold and scan speed 60- to 110-fold vs time domain OCT (TD-OCT). SD-OCT enables novel scanning, denser sampling, and 3-dimensional imaging. This thesis tests my hypothesis that SD-OCT improves reproducibility, sensitivity, and specificity for glaucoma detection. METHODS: OCT progress is reviewed from invention onward, and future development is discussed. To test the hypothesis, TD-OCT and SD-OCT reproducibility and glaucoma discrimination are evaluated. Forty-one eyes of 21 subjects (SD-OCT) and 21 eyes of 21 subjects (TD-OCT) are studied to test retinal nerve fiber layer (RNFL) thickness measurement reproducibility. Forty eyes of 20 subjects (SD-OCT) and 21 eyes of 21 subjects (TD-OCT) are investigated to test macular parameter reproducibility. For both TD-OCT and SD-OCT, 83 eyes of 83 subjects are assessed to evaluate RNFL thickness and 74 eyes of 74 subjects to evaluate macular glaucoma discrimination. RESULTS: Compared to conventional TD-OCT, SD-OCT had statistically significantly better reproducibility in most sectoral macular thickness and peripapillary RNFL sectoral measurements. There was no statistically significant difference in overall mean macular or RNFL reproducibility, or between TD-OCT and SD-OCT glaucoma discrimination. Surprisingly, TD-OCT macular RNFL thickness showed glaucoma discrimination superior to SD-OCT. CONCLUSIONS: At its current development state, SD-OCT shows better reproducibility than TD-OCT, but glaucoma discrimination is similar for TD-OCT and SD-OCT. Technological improvements are likely to enhance SD-OCT reproducibility, sensitivity, specificity, and utility, but these will require additional development.
PURPOSE: Optical coherence tomography (OCT) is a rapidly evolving, robust technology that has profoundly changed the practice of ophthalmology. Spectral domain OCT (SD-OCT) increases axial resolution 2- to 3-fold and scan speed 60- to 110-fold vs time domain OCT (TD-OCT). SD-OCT enables novel scanning, denser sampling, and 3-dimensional imaging. This thesis tests my hypothesis that SD-OCT improves reproducibility, sensitivity, and specificity for glaucoma detection. METHODS: OCT progress is reviewed from invention onward, and future development is discussed. To test the hypothesis, TD-OCT and SD-OCT reproducibility and glaucoma discrimination are evaluated. Forty-one eyes of 21 subjects (SD-OCT) and 21 eyes of 21 subjects (TD-OCT) are studied to test retinal nerve fiber layer (RNFL) thickness measurement reproducibility. Forty eyes of 20 subjects (SD-OCT) and 21 eyes of 21 subjects (TD-OCT) are investigated to test macular parameter reproducibility. For both TD-OCT and SD-OCT, 83 eyes of 83 subjects are assessed to evaluate RNFL thickness and 74 eyes of 74 subjects to evaluate macular glaucoma discrimination. RESULTS: Compared to conventional TD-OCT, SD-OCT had statistically significantly better reproducibility in most sectoral macular thickness and peripapillary RNFL sectoral measurements. There was no statistically significant difference in overall mean macular or RNFL reproducibility, or between TD-OCT and SD-OCT glaucoma discrimination. Surprisingly, TD-OCT macular RNFL thickness showed glaucoma discrimination superior to SD-OCT. CONCLUSIONS: At its current development state, SD-OCT shows better reproducibility than TD-OCT, but glaucoma discrimination is similar for TD-OCT and SD-OCT. Technological improvements are likely to enhance SD-OCT reproducibility, sensitivity, specificity, and utility, but these will require additional development.
Authors: Lelia A Paunescu; Joel S Schuman; Lori Lyn Price; Paul C Stark; Siobahn Beaton; Hiroshi Ishikawa; Gadi Wollstein; James G Fujimoto Journal: Invest Ophthalmol Vis Sci Date: 2004-06 Impact factor: 4.799
Authors: Tony H Ko; Andre J Witkin; James G Fujimoto; Annie Chan; Adam H Rogers; Caroline R Baumal; Joel S Schuman; Wolfgang Drexler; Elias Reichel; Jay S Duker Journal: Arch Ophthalmol Date: 2006-06
Authors: Michelle L Gabriele; Hiroshi Ishikawa; Gadi Wollstein; Richard A Bilonick; Larry Kagemann; Maciej Wojtkowski; Vivek J Srinivasan; James G Fujimoto; Jay S Duker; Joel S Schuman Journal: Invest Ophthalmol Vis Sci Date: 2007-07 Impact factor: 4.799
Authors: Lelia A Paunescu; Tony H Ko; Jay S Duker; Annie Chan; Wolfgang Drexler; Joel S Schuman; James G Fujimoto Journal: Ophthalmology Date: 2005-12-15 Impact factor: 12.079
Authors: Felipe A Medeiros; Pamela A Sample; Linda M Zangwill; Christopher Bowd; Makoto Aihara; Robert N Weinreb Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Alexandre S C Reis; Neil O'Leary; Hongli Yang; Glen P Sharpe; Marcelo T Nicolela; Claude F Burgoyne; Balwantray C Chauhan Journal: Invest Ophthalmol Vis Sci Date: 2012-04-18 Impact factor: 4.799
Authors: Kyung Rim Sung; Jong S Kim; Gadi Wollstein; Lindsey Folio; Michael S Kook; Joel S Schuman Journal: Br J Ophthalmol Date: 2010-10-28 Impact factor: 4.638
Authors: Michelle L Gabriele; Gadi Wollstein; Hiroshi Ishikawa; Larry Kagemann; Juan Xu; Lindsey S Folio; Joel S Schuman Journal: Invest Ophthalmol Vis Sci Date: 2011-04-14 Impact factor: 4.799
Authors: Yu-Ying Liu; Hiroshi Ishikawa; Mei Chen; Gadi Wollstein; Jay S Duker; James G Fujimoto; Joel S Schuman; James M Rehg Journal: Invest Ophthalmol Vis Sci Date: 2011-10-21 Impact factor: 4.799